Introduction
The growth of solid tumors is frequently accompanied by neovascularization. This requirement for angiogenesis implied that targeting tumor vascular endothelial cells might represent a novel therapeutic strategy (1) . Proof of principle was established through clinical applications demonstrating efficacy of the anti-vascular endothelial growth factor VEGF antibody, bevacizumab (2) .
VEGF is a potent angiogenic factor and endothelial cell-specific mitogen (3, 4, 5) that is regulated by hypoxia in vitro (6) and in vivo (7, 8, 9, 10) . This hypoxic induction of VEGF is due to an increase in the steady state level of Vegf mRNA (11) . Similar to the erythropoietin (Epo) gene (6) , the Vegf gene is induced by metal ions and hypoxia (10) . The implication of these studies is that there may be fundamental similarities in the oxygen-sensing pathway leading to the activation of these two genes. Hypoxic induction of the Epo gene appears to be regulated by both transcriptional and post-transcriptional mechanisms (12, 13, 14) . Hypoxia-inducible factor 1 (HIF-1) was identified as a protein that specifically binds to an enhancer element 3' to the Epo gene in a hypoxia-regulated fashion (15, 16) .
HIF-1 is a key regulator of responses to hypoxia, occupying a central position in oxygen homeostasis in a wide range of organisms (17) . Among its transcriptional targets are genes with critical roles in angiogenesis, erythropoiesis, energy metabolism, vasomotor function, and apoptotic/proliferative responses. HIF-1 is also essential for normal development (18) and plays key roles in pathophysiological responses to ischemia/hypoxia as well as in tumor growth and angiogenesis (17) .
HIF-1 is a heterodimeric transcription factor composed of a HIF-1 subunit and a HIF-1 subunit (19) . HIF-1 is continuously synthesized and degraded under normoxic conditions.
Under hypoxic conditions, HIF-1 degradation is inhibited, allowing the protein to accumulate and dimerize with HIF-1 . This heterodimer binds to cis-acting hypoxia-response elements in target genes and recruits coactivator proteins, all of which leads to increased transcription. In oxygenated cells, intracellular oxygen concentrations are directly sensed by HIF-1 hydroxylation enzymes, prolyl hydroxylases PHDs . PHDs tag HIF-1 subunits for polyubiquitination and proteasomal degradation by prolyl hydroxylation using 2-oxoglutarate 2-OX and dioxygen (20, 21) . Our recent studies have shown that 2-OX reduces HIF-1 , erythropoietin, and VEGF expression under hypoxic conditions in the hepatoma cell line Hep3B (22) . To address the clinical usefulness of 2-OX, we investigated its anti-tumor effect using a mouse dorsal air sac (DAS) assay and a murine tumor xenograft model. We found that 2-OX exerts potent anti-tumor effects by inhibiting angiogenesis, and we discuss the possibility of 2-OX as a novel anti-angiogenesis drug.
Material and Methods
Cell culture. The Lewis lung carcinoma LLC and B16F10 melanoma cell lines were obtained from the American Type Tissue Culture Collection (Rockville, MD, USA). Cells were incubated under both 21% (normoxia) and 1% (hypoxia) oxygen. The exposure times were as described below.
Cell proliferation assay. Cell survival was determined by a nonradioactive cell proliferation assay (Promega, WI, USA The detection limits is 3 pg/mL for VEGF.
Mice. Seven-week-old male C57BL/6J mice were purchased from Clea-Japan (Tokyo, Japan).
They were housed in autocleaning metal cages in an air-conditioned room and were offered a standard diet (CM; Oriental Yeast, Tokyo, Japan) and tap water ad libitum. This study was . However, the addition of 7.5 and 15 mM 2-OX dose-dependently reduced HIF-1α protein production (Fig. 1C, upper panel) , although the addition of 2-OX did not affect lamin B, which was used as a control (Fig.2B, lower panel) . These results suggest that 2-OX reduces the HIF-1α protein level. To evaluate the VEGF protein levels after 2-OX treatment, an ELISA assay was performed.
2-OX reduces
Hypoxia-induced VEGF protein production from LLC cells was 289.3 ± 25.6 pg/mg protein (Fig.2B) . To elucidate the dose-dependent effects of 2-OX on the production of VEGF by LLC cells, different concentrations of 2-OX were added to the cultures. Addition of 7.5 or 15 mM 2-OX inhibited VEGF protein production to 253.5 ± 17.8 and 178.6 ± 23.7 pg/mg protein, respectively (Fig.2B) . These results indicate that 2-OX inhibits VEGF protein production by LLC cells in a dose-dependent manner. Thus, consistent with the reduction of VEGF mRNA, VEGF protein is reduced by 2-OX treatment in a dose-dependent manner in LLC cells.
2-OX inhibits blood vessel formation in vivo.
To assess the effect of 2-OX on tumor angiogenesis in vivo, we performed DAS assays using LLC cells. When mice were implanted with a chamber that carried LLC cells, blood vessels characterized by strikingly disorganized and tortuous vessels were induced towards the chamber from pre-existing blood vessels beneath the epidermis (Fig.3A) . Such tumor-induced blood vessel formation was, however, reduced by the administration of 2-OX (Fig.3A) . Quantitative analysis of the values of blood vessel area by LLC cells using angiogenesis-measuring software were as follows: LLC only, 100 ± 20.8%; LLC+7.5mM 2-OX, 64.0 ± 9.4%; and LLC+15mM 2-OX, 45.6 ± 4.4% Fig.3A . In contrast, Fig.4A , B, C . These data indicate that 2-OX reduces tumor size.
We observed significant differences in microvessel density PBS alone, 100 ± 16.5 %; and 100mg/kg 2-OX, 46.0 ± 13.5 % by immunostaining for the endothelial cell marker CD31 
Discussion
Since the concentration of 2-OX and dioxygen is essential for hydroxylation and degradation of HIF-1 protein, consistent with this report, Jaakkola et al. examined a series of 2-OX analogs that act as competitive inhibitors of PHDs (26) for their ability to inhibit HIF-PHD (21) . We also reported that 2-OX treatment of Hep3B cells induced HIF-1 degradation in vitro and reduced the production of VEGF protein 22 . Treatment with 2-OX also restored PHD2 to control levels and abolished the nuclear accumulation of HIF-1 27 . Based on cell culture studies, cell-permeating 2-OX derivatives have been proposed as a new therapy to restore normal PHD activity and HIF-1 levels to those of succinate dehydrogenase-suppressed cells 28 .These in vitro studies indicate that 2-OX induces HIF-1 degradation and suppresses gene expression downstream of HIF-1. However, it was not clear whether 2-OX could be useful for suppression of tumor angiogenesis and its growth in animals. Our current study clearly shows that 2-OX reduced the HIF-1 protein level in LLC cells and reduced LLC cell-induced tumor angiogenesis in an animal model. 2-OX also reduced tumor growth in a dose-dependent manner.
It is widely recognized that targeting tumor endothelial cells is useful for tumor therapy.
Bevacizmab, a neutralizing antibody against VEGF, has been used for various tumor therapies in combination with chemoreagents 25 . In the present study, we evaluated the effect of 2-OX on higher cause a dose-dependent elevation of serum EPO, which increased hemoglobin concentrations by 1.1 g/dL above the baseline level on day 42 of the study 30 . However, as expected, based on the effects of HIF-PHD, there is concern that FG-2216 might increase expression of VEGF. The same is equally true of whole body 2-OX administration.
2-OX is a metabolite in the TCA cycle and exists in cells at relatively high concentrations.
Our study clearly showed that various concentrations had no effect on the viability of cultured cells but were sufficient to reduce tumor size. Further, 2-OX had no effect on pre-existing endothelial cells and had no effect on blood cell count in peripheral blood samples that were obtained from the retro-orbital plexus of mice data not shown . Taken together, 2-OX is a promising new therapeutic reagent with no apparent side effects for inhibiting tumor angiogenesis and tumor size.
Hypoxia has been shown to be a very important stimulus for new vessel formation as seen in coronary artery disease (31) and diabetic neovascularization (32) . HIF-1 is a key transcription factor regulating oxygen homeostasis. Arjamaa et al. showed that all oxygen-dependent diseases of the retina are regulated by HIF 33 . Thus, it will be very interesting to investigate in future if 2-OX inhibits other HIF-dependent diseases in animal models. *indicates significance compared with control, P < 0.001. ** indicates significance compared with control, P < 0.01. *** indicates significance compared with control, P < 0.025. **** indicates significance compared with control, P < 0.05. 
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